Background and aims: Home parenteral nutrition-quality of life (HPN-QOL © ) is a selfassessment tool for the measurement of QOL in patients on HPN. The aims of this study were: to re-assess the basic psychometric properties of the HPN-QOL © in a multinational sample of adult patients; to provide a description of QOL dimensions by short and long HPN treatment duration; to explore clinical factors potentially associated to QOL scores. Methods: Patients (n=699) from 14 countries completed the HPN-QOL © . The questionnaires were analysed to evaluate data completeness, convergent /discriminant validity and internal-consistency reliability. The association of overall QOL and HPN treatment duration as well as other clinical factors were investigated using multivariable linear regression models.
Introduction
Intestinal failure is defined as "the reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth" (1) . Home parenteral nutrition (HPN) is the primary therapy of chronic intestinal failure (CIF) (2) . The main aims of HPN are to increase long term survival of patients who may otherwise die of malnutrition or dehydration or should otherwise be confined to hospital and, consequently, to improve, quality of life (QOL) and to allow socio-economic rehabilitation (3) . Although patients on HPN may not achieve complete return to normality, scores can improve compared to pre-HPN (4) .
Although HPN is a life-saving therapy for patients with CIF, it does involve the infusion of nutrients into a central vein, and can radically change the life of patients who may be faced with on-going symptoms of the underlying condition but also live a complex, technologydependent lifestyle (5) . It is a time-consuming, invasive therapy used in patients who often have physical problems and who have to face many psychological difficulties as well.
Anxiety and fear are common reactions to the threat of potentially life-threatening complications of treatment such as severe infection, thrombosis and liver failure (6) , which realistically can still occur. Depression, anger, negative self-image and social limitations are frequently reported. Depression has been seen in up to 65% of patients on HPN and may have serious consequences for their therapy as it has been shown to lead to less careful catheter care and social impairment in 55% (7) . All of these factors may impact on QOL. Severe fatigue has been reported as one of the most frequent complaints -in up to 63% of HPN patients (8) , which in turn consistently affect daily activities such as work and leisure.
In 2012, the period prevalence of HPN in 16 European countries was estimated to range from 3.25 to 66 patients per million of the population (9) . The most common indication for HPN in adults is short bowel arising from underlying diseases such as mesenteric ischemia and Crohn's disease; motility disorders and bowel obstruction due to cancer (7) .
About 60-79% of patients in USA and Europe receiving HPN survive for five years or more.
At 10 years 84% are still dependent on HPN and a significant number live 20 years or longer (8) (9) (10) (11) (12) (13) (14) . In 2009 ESPEN published guidelines for the use of HPN in adults (15) and recognised the lack of studies describing QOL in HPN patients using disease-specific tools; it was noted that measurement of QOL should be patient-based rather than the clinician's perspective.
The HPN-QOL © , a self-assessment tool for measurement of QOL in patients on HPN, was originally devised within the Home Artificial Nutrition and Chronic Intestinal Failure (HAN&CIF) special interest group of the European Society for Clinical Nutrition and Metabolism (ESPEN). It underwent psychometric validation in a small sample of English patients and was then translated into Danish, Dutch, French, German, Italian, Polish and Spanish to enable international use (16) .
Hence there is the need to assess the basic psychometric performance of the questionnaire in a larger number of patients and with translations into other languages, as well as to provide a description of QOL dimensions in a sample of patients from different European countries. Moreover it was deemed interesting to explore factors that are significantly correlated with patterns/items of QOL.
The aims of the present study are:
1. to re-assess basic psychometric properties of the HPN-QOL © in a multinational sample and explore differences across the three most widely-spoken languages in our sample: English, French and Italian; 2. to provide a description of QOL dimensions in a sample of international patients, stratified by short and long HPN treatment duration;
3. to explore clinical factors associated with reported QOL.
Methods

Study design
This is a cross-sectional observational multicentre study promoted by the ESPEN HAN&CIF working group in fourteen European, North American and Australian countries.
The research was also supported by the Scientific Committee of ESPEN which assigned a grant to the principal investigator (JB) of the study. Adult patients were recruited from January to December 2010 and were eligible if they were discharged from adult hospital services on HPN. Patients were excluded if they were unable to complete the questionnaire (either self-administered or at an interview) because of mental impairment.
Quality of life measure and data collection procedure
The HPN-QOL © questionnaire was developed as a treatment specific instrument for the assessment of QOL in patients treated with HPN. It has been translated into Danish, Dutch, French, German, Italian, Polish and Spanish, using forward-backward methodology (16) . The French translation was adapted for use in Belgium and French-speaking Canada and the English version adapted for use in the US and Canada. Psychometric small-sample validation of the English version confirmed the scale structure of the questionnaire (17) .
The questionnaire contains 7 multi-item functional scales and 1 single-item functional scale, as well as 6 multi-item and 3 single-item symptom scale (17) . The functional scales include General Health (GH), Ability to Holiday or Travel (HT), Coping (CO), Physical Function (PF), Ability to Eat and Drink (ED), Employment (EM), Sexual Function (SX), and Emotional Function (EF); for these scales, a high score indicates a high level of functioning. The symptom or problem scales, in which a high score represents high severity or more problems, include Body Image (BI), Immobility (IM), Fatigue (FA), Sleep Pattern (SP), Gastrointestinal Symptoms (GI), other Pain (PA), Presence or Absence of a Stoma (ST), Financial Issues (FI), and Weight (WT). Two questions relate to nutrition teams and the availability of an ambulatory pump for infusion of HPN, in which a high score represents a good outcome. The questionnaire concludes with three 0-10 numerical rating scales (NRS) where high scores indicate high QOL. The first is a global QOL question and the other two respectively assess the effect of the underlying illness and of the HPN on overall QOL. The complete English version of the questionnaire can be found in the appendix of a previously published paper (17) .
The questionnaire was self completed by the patients, either at a scheduled outpatient visit or at home after mail delivery. 
Statistical analysis
The HPN-QOL © was scored according to scoring rules previously reported (17) . When more than 50% of items in a scale or for the whole questionnaire were missing, the scale score or the questionnaire were dropped from analysis on a patient basis; when the number of missed items was ≤ 50% for a single scale, the mean of the completed items was used for simple imputation. Scores were rescaled to range from 0 to 100 and, to further improve readability, made uniform inasmuch as high scores indicate "good condition" in all scales (i.e. high function/good status as well as low symptom or problem intensity).
Psychometric analyses (Aim 1 of the study) evaluated the following aspects: data completeness, convergent /discriminant validity and internal-consistency reliability. Data completeness was measured by the percentages of missing scale scores. Convergent and discriminant validity were assessed through multitrait-scaling analysis (18) which explores the relationships of each item and the hypothesized scales. Convergent validity indicates a relevant correlation between an item and the scale to which it belongs. Correlations were corrected for overlap. Pearson correlation coefficients ≥0.4 support convergent validity (18) . Discriminant validity is supported whenever a correlation between an item and its hypothesized scale is higher than the correlation with the other scales. Internalconsistency reliability of multi-item scales was measured by Cronbach's alpha; alpha values above 0.7 are generally regarded as acceptable for group comparison (18) .
Psychometric analyses were performed on the overall sample and within the three largest language subsamples: English, French and Italian. Items not fitting with the predefined psychometric criteria on the overall sample were candidates for dropping or modification. Aims 2 and 3 of the study were addressed with the use of a multivariable linear regression models in which the overall QOL assessment identified by the item 44 (how has your QOL been in the last week?) was the dependent variable. In a first analysis ("main model") the following variables were considered as predictors: HPN treatment duration (classified as short or long using a 24-month cut-point), age (continuous covariate), gender, living status, functional status and presence of a stoma. Language and underlying disease (categorical covariates) were modelled in the regressions using dummy variables. Stepwise backwarddeletion of non-significant regression covariates was used. This analysis was carried out in the set of 451 records with complete information. A second analysis ("extended model") was carried out in a set of 424 records that in addition contained a number of HPN details (indication, type of supply, days and hours of infusion). Although of clinical interest, these features are likely to reflect treatment decisions that had been based on patient and disease characteristics, and may thus originate some degree of confounding. Therefore, we followed a "two-step" strategy in which the first modelexplored prognostic effects of patient and disease characteristics, and the second included the effect of treatment details while adjusting for the other factors. Results are reported in terms of estimated regression coefficients (beta), corresponding 95% confidence limits (95% CLs) and overall p values at the Wald's test, respectively for the main and extended models. The conventional twosided 5% level was chosen as the threshold of statistical significance. Statistical analyses were carried out with SAS (version 9.2, SAS Institute, Cary, NC) and R software (version 3.1.1, R Foundation for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
Six hundred and ninety-nine patients accepted to participate into the study and returned the questionnaire. Statistical analyses included 691 patients, after excluding eight questionnaires with more than 50% missing items.
More patients were female (61.6%) than male, with a median age of 54 years (range, 17-94) and with a varied geographical distribution (Table 1) Despite various reminders to participating centres, many socio-demographic and clinical data collection forms were not returned thus resulting in missing data.
Psychometric evaluation of the HPN-QOL ©
Preliminary multitrait-scaling and internal consistency analyses indicated a bad fit of items 4 (burden of HPN), 20 (ability to socialize), 30 (nausea and vomiting) and 41 (bowel movements) with respect to the original questionnaire structure. These items were therefore excluded from their respective scales (CO, PF, GI and NoST) and regarded as single item scales ( Table 2 ). The two 0-10 NRS items assessing the effect of illness and the effect of HPN on global QOL showed 11% and 12% of missing data, respectively .
These figures match with results from the previous validation study where patients reported a difficulty to distinguish between the effect of illness and of HPN on QOL (16) .
For these reasons the two items were dropped from the analysis.
Results of psychometric analyses carried out on the modified questionnaire structure are shown in Table 2 . Most scale-specific average scores were consistently around 60 to 70, with the exception of sexual function, holiday/travel, employment and physical function which scored below 50. Item level missing-value rates -not shown in Table 2 -were low, ranging from 0% to 6%, except for the two items related to sex (17% and 20% missing).
Accordingly, completeness was good for most scales (Table 2) (Table 2) were also satisfactory for all the comparisons performed. QOL NRS in particular yielded a median correlation with other scales of 0.32, data not reported in table (range 0.14-0.53, 5 correlations>0.4); given the content of the scale, fairly high values were expected and may be considered acceptable. Internal consistency reliability was good for most of the multi-item scales, with Cronbach's α coefficients generally higher than the 0.70 benchmark, or only slightly below the benchmark for EM (α=0.65), GI (α=0.66), PA (α=0.65) and noST (α=0.54).
Psychometric evaluation of the HPN-QOL © in the different English, French and Italian language patient sub-groups (Supplementary Tables A1, A2 and A3) provided results similar to those in the overall sample, thus confirming the good quality of these cultural adaptations.
Investigation of QOL associated factors
Results of the multivariable linear regression modelling are shown in Table 3 . In the "main model" age, gender, functional status, presence of stoma and language failed to achieve statistical significance. Better overall QOL scores were observed in patients with HPN duration longer than 24 months compared to patients with shorter duration (beta=0.55, 95%CL: 0.12 -0.98; P=0.013). With the procedure described in the Methods Section, two clusters were detected for underlying disease in terms of outcome. Better QOL was observed in patients with Crohn's disease or mesenteric ischaemia compared to patients with other diseases (cancer, motility disorders, radiation enteritis or unspecified conditions). The corresponding beta coefficient was 0.65 (95% CL:0.25 -1.06; P=0.002).
Patients living alone tended to be disadvantaged in terms of QOL outcome compared to The "extended model", investigating the role of the HPN characteristics adjusted for the other factors showed a significant result only for HPN days of infusion per week. In particular, the negative coefficient denoted a worsening overall QOL for an increasing number of infusion days.
Discussion
This paper represents the final stage of developing the HPN-QOL © , carried out on behalf of the HAN&CIF Special Interest Group of ESPEN. It started with a review of the instruments used to assess QOL of adult patients with CIF receiving HPN and an evaluation of the state of art of this topic (3, 19) and then progressed with generation of QOL issues, production of a provisional questionnaire and its pre-testing (16) . The scale structure of the questionnaire was initially tested for reliability and validity in a preliminary sample of 100 patients and showed positive results under the psychometric and clinical profile (17) .
The present study went further by analyzing the psychometric properties of the questionnaire in a wider multi-language sample. In particular, multitrait-scaling and internal consistency analyses indicated a good fit with respect to the original questionnaire structure for most items. Exceptions were items 4 (burden of HPN), 20 (ability to socialize), The "main model" of the multivariable linear regression showed that QOL score was significantly dependent on the type of the underlying disease, the duration of the HPN treatment and the living status. The "extended model" indicated that, when adjusted for factors identified by the "main model", the number of days of HPN per week has also a significant impact of QOL. Better QOL scores were observed in patients with Crohn's disease or mesenteric ischemia compared to patients with other kinds of disease (cancer, motility disorders, radiation enteritis or unspecified conditions). By showing better overall QOL in patients with longer HPN duration, this study is in agreement with the results of previous works (20, 21) indicating that patients are able to cope with their illness over time with a possible improvement in QOL. Although reasonable, this interpretation must be taken with caution considering that the cross-sectional study design does not allow the more direct assessment of time trends that would be possible with a longitudinal design. QOL is influenced by both the gastrointestinal illness and the effects of HPN treatment. To disentangle these effects, it would be necessary to prospectively study QOL scores in a cohort of patients who are candidates for HPN, prior to and after HPN. Such evidence cannot be achieved by a cross-sectional study like the present one. The finding that living alone is associated with worst QOL scores was also expected and can be explained by the complex technology of HPN administration that requires expertise in managing needles and bags with sterility as well as the invaluable role of an always available caregiver.
A number of studies have assessed QOL of patients requiring HPN but care must be taken when comparing their results with ours, as the majority of these studies relied on generic QOL tools that were neither tailored to nor validated in this patient population (19) .
The actual role of HPN characteristics on QOL of patients with CIF, such as days of infusion per week and hours of infusion per day, is a key question. Indeed, HPN is the primary therapy of CIF and therefore is dependent on the characteristics of the underlying disease as well as pathophysiological mechanism of CIF (1). In a previous short term prospective follow up study on a small patient population, where QOL assessment was performed using the SF-36, a generic assessment tool, it was observed that the reduction of QOL was associated with an increase of HPN days of infusion per week. That result was considered to represent a deterioration of the intestinal failure (22) . Nevertheless, the data of the present study indicate that, when adjusted for the major factors influencing QOL, the number of HPN infusion per week has a significant role. This agrees with data of a study on patients with short bowel syndrome, where QOL was assessed using a validated SBS-QoL TM scale (23) . In this cohort of patients, having the same underlying disease characteristics, the reductions in volume of HPN infusion (and therefore of hours and/or days of infusions) were associated with improvements in QOL scores. In 2014, the ESPEN HAN&CIF group carried out an international multicentre study aimed to identify the top 3 most important outcome indicators (out of a list of 9 proposed), according to patients' perspectives (24) . QOL was the third of the top 3 indicators, the incidence of catheterrelated infection and survival rate being the first two. Interestingly, for one of the nine outcome indicators (freedom and independence), there was a significant difference among patients categories based on HPN regimen (number of HPN day per week) and on HPN experience. Independence was rated more important for less experienced patients (HPN duration <2 years). Most of the less experienced patients received HPN on 7 days per week, whereas experienced patients had between 3 and 6 HPN days per week.
Concerning the HPN regimen, patients with 6 or 7 HPN days consistently found independence important. This was not the case for patients with 5 HPN days or less per
week (24) . Patients were also asked to propose new indicators. Among those, two new indicators related to QOL were identified "keeping the problems related to my underlying disease as low as possible" and "maximizing HPN-free days" (24) . Overall, our results and those from previous studies suggest that the burden of the underlying disease plays a primary role in determining QOL of patients on HPN for CIF and that, after optimizing the disease control, QOL could be further improved by reducing the HPN burden as much as possible.
There are a few limitations of this study. In the first place, information on sociodemographic and clinical data was not complete for as much as 35.5% of the patients originally entered into the study. This was due to administrative problem in some centres which performed only patient reported outcome assessment with HPN-QOL © . Secondly, in spite of the considerable overall sample size, the number of patients for some language versions (German, Dutch, Danish, Polish and Spanish) was too small for distinct psychometric testing. More language specific data will be likely available if the HPN-QOL © becomes embedded into routine clinical practice. The measurement of QOL should be included in the list of clinical quality indicators identified as part of the global attempt at raising the quality of clinical care (18) ; particularly since most patients are provided with HPN to either maintain or improve QOL. Finally, our cross-sectional study design could not address HPN-QOL © questionnaire's test-retest reliability and responsiveness to change, and these aspects will therefore have to be assessed in future studies.
In conclusion, this investigation responds to the lack of evidence regarding QOL assessment in patients undergoing HPN, and has the potential to integrate ESPEN guidelines. The results have both theoretical and practical implications. Many clinical services are inviting patients to respond to Patient Reported Outcome Measures including QOL and satisfaction with the service they receive. By embedding the assessment of QOL into routine clinical care clinicians will be provided with the necessary outcome evidence that ensures good patient centred care (25) . Finally, the HPN-QOL © here presented may also be used as a research tool in clinical trials.
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